NetScientific says it is well place to realise 'optimal shareholder value'
The comments follow a turnaround year for the business
Company
LON:NSCI
EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, the group invests in, manages, and strengthens early stage IP-rich companies.
422 stories · page 2 of 5
The comments follow a turnaround year for the business
"Following strong progress in 2021, PDS is now approaching significant potential value inflection points"
The board sees "substantial upside potential" through a multi-pronged growth strategy
“The company's careful planning and successful fund-raise in 2021 - in which NetScientific participated - has positioned PDS well to weather market volatility"
PDS Biotech's candidate drug PDS0101 likely safe and well tolerated in first 18 trial patients
The trial will be completed with PDS0101 alone or in combination with the checkpoint inhibitor Keytruda
PDS0101 will now progress to the full enrolment of 54 patients
London-listed NetScientific has a 5.7% interest in the US bio-tech which has announced positive preclinical data
"PDS' growing patent portfolio positions the company well for success, as the company continues to progress its clinical trials," said NetScientific boss Ilian Iliev
"We are delighted with the continued progress being made at ProAxsis with accelerated developments, new products and additional revenue streams in 2022," said chairman John Clarkson
The transaction helps diversify the company's investment portfolio
“The deal demonstrates NSCI's capital-light investment approach, is additive to NSCI's balance sheet"
"The Martlet Capital team has hit the ground running, resulting in further growth opportunities for NetScientific as we gain exposure to the excellent deal flow from the Cambridge cluster."
EpiBone creates a personalized 'scaffold' of the required replacement bone and, using a custom bioreactor and stem cells from your body, 'incubate' a new bone and remodels it as a personalised bone graft
There was cash and cash equivalents approximately $69.7mln at the end of September
Sofant is a specialist in 5G communications and an antenna developer. NetScientific has a 23.5% interest in the Edinburgh-based business
PDS Biotech has announced an agreement with the University of Georgia to license novel proteins for Versamune-based universal flu vaccine
"This investment exemplifies NetScientific's capital-light investment model into exciting technology companies," said Dr Ilian Iliev, the CEO of NetScientific
"The K-POSTN assay has the potential to help healthcare professionals screen, identify and/or monitor people most at risk of osteoporotic fractures and other bone diseases, thus enabling early therapeutic intervention," said ProAxis CEO Dr
The issue is said to be unrelated to any safety or efficacy concerns with the drug combination
The initial arm of this phase II trial will assess people who have not yet been treated with checkpoint inhibitor drugs
The company invests in emerging life sciences and tech companies - and has uncovered a handful of hidden gems, say WHI Ireland
“We are seeking to address the continued disconnect between the fair value and growth opportunities of the group, and the current market cap," said Ilian Iliev
It is investing an initial £1mln in Martlet Capital, which has been set up to up to acquire minority interests in businesses in this hotbed of innovation
"The company is now well-positioned for future success"
The funding from this offering will support the continued development of PDS's lead HPV oncology candidate (PDS0101) in the three Phase II trials currently underway.
WHI Ireland has a sum-of-the-parts valuation for the shares of 162p - a 40% premium to the current price
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
NetScientific currently has a 5.7% stake in PDS Biotechnology, which is at the cutting edge of immuno-oncology
Archive
A look at some of the big movers in the small-cap world this week
"This placement provides further impetus behind our model of 'capital-light' investment combined with pro-active management and value-added support to our portfolio," said Ilian Ilev, NetScientific's CEO
“The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients"
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A look at some of the major movers in London on Monday
It is envisaged that the validation and initial commercialisation can be achieved largely from ProAxsis' existing resources
Investments and investor services
The easiest way to describe NetScientific is a ‘reset story’. By this I mean new management has come in, cut costs, refinanced, refocused, and, hopefully, put the business back on the guide rails to success.
The City broker pointed to the last fair value calculation for the assets held by the investment company, which specialises in life sciences and technology
Archive
A glance at some of the day's highlights from the Proactive Investors' newswire
Chairman John Clarkson said: “In what has been a challenging year for ProAxsis, positive management actions have helped transform the company’s outlook"
The latest data points to a 71% response rate to the drug
"We worked with the management team throughout the COVID crisis to help evolve corporate and investment strategy in response to the once-in-a-generation shifts in corporate practices unleashed by COVID,” said NetScientific chief executive D
The company said PDS has received US$4.5mln from the sale of the benefits, which fall under the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program
The company said the Innovate UK grant will co-fund a £390,000 project to develop novel protease biomarkers to identify high-risk COVID-19 patients
Glycotest Inc has received US$3mln, which help fund the commercialisation of its liver cancer diagnostic
NetScientific invested £1.76mln for a 14.85% shareholding in PDS Biotechnology
Portfolio company PDS intends to “continue to advance our previously announced combination studies with PDS0101 in various advanced HPV-associated cancers”
PDS said 60% of patients in a Phase 1 trial had responded to PDS0101, which is aiming to treat high-risk, cancer-causing types of HPV
The agreement will see the PDS direct Aspire Capital to buy up to 100,000 shares per day whenever the stock price exceeds 50 US cents
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's major movers, including Karelian, UniVision, Cambria Africa, Bagir, Nautilus Marine, Stride Gaming and Patagonia Gold
The data, published in the peer-reviewed European Respiratory Journal, found that NEATstik was able to replicate the results of existing tests for chest infections within only ten minutes
Investments and investor services
The Dow Jones suffered a 300 point fall in the first half hour of trading
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
Archive
A look at some of the top risers and fallers on the London Stock Exchange on Wednesday, including 21st Century Technology, Thruvision, Hargreaves Services, Management Resource Solutions, SafeCharge International, IG Group, Pets at Home, and
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
CEO Ian Postlethwaite said the healthcare commercialisation firm had taken measures to reduce its central function costs and was expected to have sufficient cash to operate until the end of 2020
Archive
The Footsie closed out at 7,334 - up around five points, while mid-cap index was firmly lower- down 129 points at 19,307
In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's major movers, including Image Scan, Water Intelligence, Laura Ashley, Gulf Marine, Synectics and Synnovia
Archive
The FTSE 100 index closed 37.62 points, or 0.5% lower at 7,434.13, albeit above the session low of 7,405.99 as US stocks continued to post big falls on Thursday
Investments and investor services
A look at the day's major movers, including Quixant, Aeorema, SpaceandPeople, RedT Energy, IFG Group and Pantheon Resources
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The group said after the close on 22 March that it would use the proceeds of the sale towards its ongoing working capital requirements
Investments and investor services
The UK's premier share index closed down around 30 points at 7,177
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's major movers, including Tern, Mears, Elecosoft, Polypipe, Softcat and NAHL
Archive
The Footsie added 0.34% to close at 7,324, while US shares are also higher at the time of writing
Investments and investor services
NetScientific also announced that PDS and Edge Therapeutics have completed their all-share merger
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A look at some of the top risers and fallers in London on Thursday.
The company is currently trying to reduce its costs “significantly” in order to invest as much of its remaining cash as possible into its portfolio companies
Archive
Footsie closed around 26 points higher at 7,185, while FTSE 250 added around 103 points at 19,283
NetScientific has decided to postpone its general meeting.
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The firm said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” so as much of its remaining cash as possible could be allocated to its portfolio compani
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The group said the initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun
The transatlantic healthcare IP commercialisation group announced on 26 November 2018 that it had decided to conduct a review of the various strategic options open to it, one of which was a sale
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's maor movers, including Carnival, EKF, Chamberlin, Panthera, NetScientific and Yu Group
The board believes that the market is undervaluing NetScientific's portfolio
"Investors aren’t willing to forgive Fed Chair Jeremy Powell yet; a soft open on Wall Street threatens to drag the FTSE lower into the close," said Fiona Cincotta at City Index
Bosses believe the market is undervaluing the strength of NetScientific’s portfolio, and as such, thinks the best way to maximise shareholder value is to sell off all or parts of the business
The company said the all-share merger was expected to create a publicly traded biotech company specialising in immune-oncology and treatments for early and late-stage cancer
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's poppers and droppers, including JD Wetherspoon, Gattaca, Renewi, AdEPT, The Works, Coca-Cola HBC and Micro Focus
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The healthcare IP commercialisation group said the study introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells
Investments and investor services
The focus is now on the Federal Reserve meeting later. The interest rate announcement is set for 7.00pm, UK time
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some big winners and losers in the UK equity market during Thursday's trading session
The firm said STRATEC would assist Vortex in producing a customised chip, a crucial component of its VTX-1 liquid biopsy platform
The bank suggested there could be a faster pace of hikes if the UK gets a smooth Brexit deal